tranylcypromine

Suppliers by country/region

• China(39)
• United States(8)
• South Korea(1)

Company Type

• Trader
• Manufacturer
• Reagent
• Service provider

Properties

Safety Information

Use

Tranylcypromine, a monoamine oxidase inhibitor (MAOI), was introduced in 1961 for the treatment of depressive illness. By 1964 its use had been associated with transient hypertensive crises and other adverse effects when taken together with certain cheeses and other foods containing tyramine. This led to the withdrawal of the drug in several countries and the suspension of marketing on a worldwide basis by the major manufacturer pending review of these adverse reactions. Subsequently, in response to requests from the medical profession, tranylcypromine was resubmitted for registration with appropriate warnings in the product information and it is now marketed in more than 30 countries.